عربي
Rhizen Pharmaceuticals AG Announces Promising Interim Data Presentation From an Ongoing Phase II Study of Tenalisib...
BASEL, Switzerland -Thursday 5 May 2022 
Rhizen Pharma reports encouraging initial results from an ongoing phase II trial to evaluate Tenalisib (RP6530; isoform selective dual PI3K δ/γ inhibitor with additional SIK3 inhibitory activity) in patients with locally advanced or metastatic breast cancer (mBC) Tenalisib was...
Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022
-Thursday 14 April 2022
Rhizen Pharma announces presentations at AACR showcasing its differentiated clinical stage PARP and DHODH programs Preclinical data on Rhizen’s differentiated PARP inhibitor RP12146, indicates a superior haematological safety profile that the company expects will translate...
Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase I/Ib Study of Its Novel PARP Inhibitor (RP12146) in...
-Saturday 6 November 2021
Rhizen Pharma commences dosing in a phase I/Ib trial to evaluate its novel PARP inhibitor (RP12146) in patients with advanced cancers. Rhizen indicated that RP12146 has comparable preclinical activity vis-à-vis approved PARP inhibitors and shows improved preclinical safety that it expects...
Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530) in Locally Advanced...
-Thursday 14 October 2021
Rhizen Pharma commences dosing in a phase II trial to evaluate Tenalisib (RP6530; isoform selective dual PI3K δ/γ inhibitor with additional SIK3 activity) in patients with locally advanced or metastatic breast cancer This multi-center, randomized phase II study is being conducted in...
Rhizen Pharmaceuticals AG Announces First Patient Dosed in a Phase 2 Study of RP7214 in Covid-19 Patients
-Wednesday 22 September 2021
First study of RP7214, a DHODH inhibitor, in Covid-19 patients with mild, symptomatic disease on the background of promising preclinical efficacy & Phase 1 healthy volunteer safety Randomized, placebo-controlled Phase 2 study is designed to evaluate the effect of RP7214 on viral...
Rhizen Pharmaceuticals AG Announces That Its Partnered Asset, Umbralisib (UKONIQ™), Has Received US FDA...
-Tuesday 9 February 2021
(BUSINESS WIRE)-- Rhizen Pharmaceuticals, a clinical-stage oncology-focused biopharmaceutical company, today announced that its novel next generation PI3K-delta inhibitor, Umbralisib, which was licensed to TG Therapeutics (NASDAQ:TGTX), has secured US FDA accelerated approval for the treatment...
Rhizen Pharmaceuticals SA Announces Presentation of the Interim Results of the Phase I/II study of Tenalisib (RP6530) in... -Sunday 6 December 2020
(BUSINESS WIRE)-- Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced presentation of the interim results of a Phase I/II combination study of Tenalisib with Romidepsin for relapsed/refractory T-Cell Lymphoma patients at the upcoming...
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1... -Tuesday 1 December 2020
(BUSINESS WIRE)-- Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The...